Celcuity (CELC) Shares Outstanding (Weighted Average) (2016 - 2025)
Celcuity (CELC) reported Shares Outstanding (Weighted Average) of $46.8 million for Q4 2025, up 18.53% on a YoY basis from $39.4 million in Q4 2024, and down 1.75% quarter-over-quarter from $47.6 million in Q3 2025.
Celcuity (CELC) Shares Outstanding (Weighted Average) (2016 - 2025) Analysis & Trends
Celcuity has reported Shares Outstanding (Weighted Average) for 10 years, with the latest figure at $46.8 million in Q4 2025.
- For the quarter ending Q4 2025, Shares Outstanding (Weighted Average) rose 18.53% year-over-year to $46.8 million; the trailing twelve-month figure through Dec 2025 stood at $46.8 million (up 18.53% YoY), and the FY2025 full-year result was $46.8 million, up 314.93% from the prior year.
- Shares Outstanding (Weighted Average) for Q4 2025 stood at $46.8 million, down from $47.6 million in the prior quarter.
- The five-year high for Shares Outstanding (Weighted Average) was $47.6 million in Q3 2025, with the low at $11.1 million in Q1 2021.
- Historically, Shares Outstanding (Weighted Average) has averaged $26.7 million across 5 years, with a median of $22.0 million in 2023.
- Annual changes were most pronounced in 2021 — Shares Outstanding (Weighted Average) advanced 7.98% — and 2024, when it jumped 93.48%.
- Celcuity's Shares Outstanding (Weighted Average) stood at $13.4 million in 2021, then gained by 15.21% to $15.4 million in 2022, then soared by 53.58% to $23.7 million in 2023, then soared by 66.6% to $39.4 million in 2024, then rose by 18.53% to $46.8 million in 2025.
- The last three Shares Outstanding (Weighted Average) figures came in at $46.8 million (Q4 2025), $47.6 million (Q3 2025), and $43.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 417.01 Bn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 928.40 Mn |
| 10 | Celcuity | 4.14 Bn | 3.42 Bn | - | 46.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 46.76 Mn |
| Sep 30, 2025 | 47.59 Mn |
| Jun 30, 2025 | 43.66 Mn |
| Mar 31, 2025 | 43.05 Mn |
| Dec 31, 2024 | 39.45 Mn |
| Sep 30, 2024 | 42.79 Mn |
| Jun 30, 2024 | 38.44 Mn |
| Mar 31, 2024 | 33.61 Mn |
| Dec 31, 2023 | 23.68 Mn |
| Sep 30, 2023 | 22.12 Mn |
| Jun 30, 2023 | 21.96 Mn |
| Mar 31, 2023 | 21.68 Mn |
| Dec 31, 2022 | 15.42 Mn |
| Sep 30, 2022 | 14.94 Mn |
| Jun 30, 2022 | 14.92 Mn |
| Mar 31, 2022 | 14.92 Mn |
| Dec 31, 2021 | 13.38 Mn |
| Sep 30, 2021 | 12.87 Mn |
| Jun 30, 2021 | 11.85 Mn |
| Mar 31, 2021 | 11.07 Mn |